Lloyd joined Persistence Capital Partners in 2010 after a career as a successful healthcare entrepreneur and corporate leader. In his capacity as Special Advisor, Lloyd currently serves as Chairman of LMC Diabetes & Endocrinology, a PCP portfolio company since 2014.
In 2013, Lloyd was honored as the Financial Times’ Outstanding Director of the Year for his role as an independent member of the Board of Directors of Valeant Pharmaceuticals International (NYSE:VRX). Lloyd also serves on the Board of the GBC American Fund and on the Advisory Council of the School of Science at Brandeis University. He has previously served as a director of several public and private corporations in the U.S. and Canada.
Lloyd has a history as a CEO, developing, leading and selling healthcare companies. He served as CEO of Thallion Pharmaceuticals (TSX:TLN), a biotechnology company sold to Bellus Health in 2013; as founding CEO of Caprion Pharmaceuticals (now Caprion Proteomics, acquired by Chicago Growth Partners in 2013), a proteomics laboratory services company; and CEO of Advanced Bioconcept, an early innovator in the development and sale of novel discovery tools for life science research, which was sold to NEN Life Sciences Products (now PerkinElmer, Inc.) in 1998. Lloyd began his career as a management consultant with McKinsey & Co.
Lloyd holds a BA in politics from Brandeis University and an MBA (Hons.) from Harvard Business School.